Formulation, Optimization and Characterization of Rifampicin Loaded Solid Lipid Nanoparticles for the Treatment of Tuberculosis.

Formulation, Optimization and Characterization of Rifampicin Loaded Solid Lipid Nanoparticles for the Treatment of Tuberculosis. Drug Dev Ind Pharm. 2018 Jul 30;:1-48 Authors: Chokshi NV, Khatri HN, Patel MM Abstract Mycobacterium tuberculosis, being the causative infectious agent, is the leading cause of death worldwide amongst the infectious disease. The low bioavailability of rifampicin (RIF), one of the vital constituent of anti-tubercular therapy, instigates an urge to develop nanocarrier, which can prevent its degradation in the acidic pH of the stomach. Solid lipid nanoparticles (SLNs) have been proven to be promising versatile platform for oral delivery of lipophilic drugs. Therefore, the current investigation demonstrates development of rifampicin loaded solid lipid nanoparticles (RIF-SLNs) using high-pressure homogenization technique by employing a three-level, three-factor Box-Behnken design. Concentration of drug, concentration of emulsifier and homogenization pressure were selected as an independent variables, and %drug loading(%DL), %entrapment efficiency(%EE) and particle size were selected as dependent variables. The developed RIF-SLNs were characterized for particle size, polydispersity index, zeta potential, %EE, %DL, DSC, XRD and TEM analysis. The mean diameter of RIF-SLNs was found to be 456 ± 11 nm, %EE of 84.12 ± 2.78%, and %DL of 15.68 ± 1.52%. The in vitro lipolysis experiments revealed that RIF-SLNs stab...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research